Screener
Niagen Bioscience NAGE Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$29.8MMiss by $747.3K
EPS$0.01Beat by $0.00
Revenue estimate$30.5M
EPS estimate$0.01
“During the quarter, Tru Niagen continued to demonstrate its category leadership, and at the same time, we laid the foundation strategically for what we expect will unlock tremendous value for years to come. The launch of our telehealth business and pharmaceutical program are long-term growth drivers that have evolved Niagen from a nutritional supplement business to a multi-asset anti-aging company. Our underlying consumer products business is the engine funding the rest of our value accretive initiatives and we are focused on investing across our multiple strategic growth opportunities, while maintaining cash flow of the business.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$34.4M
EPS estimate$0.01
Valuation & ratios
Valuation
as of 08/27/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Niagen Bioscience report Q2 2026 earnings?
- Niagen Bioscience (NAGE) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Niagen Bioscience's Q2 2026 revenue and EPS?
- Niagen Bioscience reported revenue of $29.8M and eps of $0.01 for Q2 2026.
- Did Niagen Bioscience beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $30.5M by $747.3K. EPS beat the consensus estimate of $0.01 by $0.00.
- How did Niagen Bioscience's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 4.3% from $31.1M a year earlier and eps declined 75.0% from $0.04.
- Where can I find Niagen Bioscience's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001386570-26-000042) and the 10-Q periodic report (0001386570-26-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.
